Journal
THERANOSTICS
Volume 8, Issue 9, Pages 2521-2548Publisher
IVYSPRING INT PUBL
DOI: 10.7150/thno.23789
Keywords
nanoparticle; magnetic resonance imaging; relaxivity; contrast agents; surface modification
Categories
Funding
- Department of Defense (CDMRP grant) [CA140666]
- National Science Foundation (CAREER grant) [NSF1552617]
- National Institutes of Health [R01EB022596, R01NS093314]
- National Natural Science Foundation of China (NSFC) projects [81271606, 81571708, 81501506]
- Norman Bethune Program of Jilin University [2015219]
- NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB022596] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS093314] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Magnetic resonance imaging (MRI) is one of the most widely used diagnostic tools in the clinic. To improve imaging quality, MRI contrast agents, which can modulate local T-1 and T-2 relaxation times, are often injected prior to or during MRI scans. However, clinically used contrast agents, including Gd3+-based chelates and iron oxide nanoparticles (IONPs), afford mediocre contrast abilities. To address this issue, there has been extensive research on developing alternative MRI contrast agents with superior r(1) and r(2) relaxivities. These efforts are facilitated by the fast progress in nanotechnology, which allows for preparation of magnetic nanoparticles (NPs) with varied size, shape, crystallinity, and composition. Studies suggest that surface coatings can also largely affect T-1 and T-2 relaxations and can be tailored in favor of a high r(1) or r(2). However, the surface impact of NPs has been less emphasized. Herein, we review recent progress on developing NP-based T-1 and T-2 contrast agents, with a focus on the surface impact.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available